Biolevate raises €30M Series A and opens Boston office for its life sciences AI
The Paris-based company Biolevate, which develops AI automation for use in regulated life sciences, has raised €30m in its Series A funding and has opened an office in Boston.
Orange Ventures and RAISE France co-led the fundraising exercise, with the company stating that RAISE France is the investment arm of Aymar Hénin, a French entrepreneur.
The MSD Global Health Innovation Fund, Station F, and the existing investor EQT Ventures were also involved. EQT led the Biolevate €6m seed round in November 2024, when the startup was focused on medical writing.
The company was founded by former Dataiku engineers and AI researchers and initially aimed to speed up the process of obtaining regulatory approval.
Its agentic platform converts scientific and regulatory knowledge into auditable workflows, with each output linked to the evidence supporting it and still requiring a person to sign off.
The platform covers the entire process from early...
Copyright of this story solely belongs to thenextweb.com. To see the full text click HERE
